Clinical Trial

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Study acronym: LCN RESCU
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-04-14; most recent amendment 2026-05-29.
Status change: Not Yet Recruiting → Recruiting 2023-10-18
Trial Details
NCT Number NCT05832229
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators: The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California
Conditions Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Enrollment 256 participants
Start Date 2023-12-07
Primary Completion 2029-08-31 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02